Trials / Sponsors / Yana Najjar
Yana Najjar
Academic / Other · 8 registered clinical trials — 5 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Recruiting | Evaluation of Hypoxia in Primary Melanoma Melanoma | — | 2025-04-09 |
| Recruiting | RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis Melanoma | EARLY_Phase 1 | 2024-03-07 |
| Recruiting | Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors a Melanoma, Unresectable Solid Tumors, Neoplasms | Phase 1 | 2021-11-29 |
| Recruiting | Evolution of Metabolic and Immune Dysfunction in In-transit Melanoma Melanoma | — | 2021-02-24 |
| Completed | Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma Advanced Melanoma, Unresectable Melanoma | Phase 2 | 2020-12-18 |
| Recruiting | A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma Advanced Melanoma | Phase 1 | 2018-02-07 |
| Terminated | Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma Melanoma | Phase 1 | 2016-07-13 |
| Completed | Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b Melanoma | Phase 1 | 2015-03-06 |